TransMedics Group, Inc. $TMDX Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 78.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,048 shares of the company’s stock after buying an additional 20,750 shares during the quarter. Envestnet Asset Management Inc. owned about 0.14% of TransMedics Group worth $5,279,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amalgamated Bank boosted its holdings in shares of TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after acquiring an additional 80 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after purchasing an additional 100 shares during the period. Smartleaf Asset Management LLC lifted its position in TransMedics Group by 24.5% during the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after purchasing an additional 108 shares during the period. State of Wyoming boosted its holdings in TransMedics Group by 20.9% in the third quarter. State of Wyoming now owns 683 shares of the company’s stock valued at $77,000 after purchasing an additional 118 shares during the last quarter. Finally, TD Waterhouse Canada Inc. boosted its holdings in TransMedics Group by 26.5% in the third quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock valued at $69,000 after purchasing an additional 126 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Morgan Stanley lifted their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Needham & Company LLC raised their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Stock Up 1.0%

Shares of NASDAQ TMDX opened at $134.25 on Monday. The stock has a market cap of $4.59 billion, a P/E ratio of 54.35 and a beta of 2.06. The business’s fifty day simple moving average is $132.50 and its 200-day simple moving average is $125.92. TransMedics Group, Inc. has a 12-month low of $62.07 and a 12-month high of $156.00. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director David Weill sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 8,920 shares of company stock valued at $1,257,310. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.